<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4753">
  <stage>Registered</stage>
  <submitdate>17/07/2014</submitdate>
  <approvaldate>17/07/2014</approvaldate>
  <nctid>NCT02201108</nctid>
  <trial_identification>
    <studytitle>Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis</studytitle>
    <scientifictitle>A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension</scientifictitle>
    <utrn />
    <trialacronym>TERIKIDS</trialacronym>
    <secondaryid>PIP - 2011-005249-12</secondaryid>
    <secondaryid>EFC11759</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Teriflunomide HMR1726
Treatment: drugs - Placebo

Placebo Comparator: placebo - Matching placebo tablets

Experimental: Teriflunomide - teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent


Treatment: drugs: Teriflunomide HMR1726
Pharmaceutical form:film-coated tablet Route of administration: oral

Treatment: drugs: Placebo
Pharmaceutical form:tablet Route of administration: oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to first clinical relapse after randomization</outcome>
      <timepoint>over 96 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of relapse free patients</outcome>
      <timepoint>at 24, 48, 72 and 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of of new/newly enlarged T2 lesions</outcome>
      <timepoint>at 24, 48, 72 and 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of T1 Gd-enhancing T1 lesions</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in volume of T2 lesions</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in volume of T1 hypointense lesions</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of new T1 hypointense lesions</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients free of new or enlarged MRI T2-lesions</outcome>
      <timepoint>at 48 weeks and 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brain atrophy</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in performance on symbol digit modalities test (SDMT) and Cognitive Battery Test</outcome>
      <timepoint>at randomization, then every 24 weeks (SDMT only) and at 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety, as assessed by clinical, laboratory, ECG, and vital signs events</outcome>
      <timepoint>over 96 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of PK parameter - lowest concentration of drug in the blood measured after dosing (Ctrough)</outcome>
      <timepoint>at Weeks 2, 3, 4, 8, 12, 24, 36 and 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Patients with relapsing multiple sclerosis are eligible. Patients should meet the
             criteria of MS based on McDonald criteria 2010 and International Pediatric Multiple
             Sclerosis Study Group (IPMSSG) criteria for pediatric MS, version of 2012 (5) and
             have:

               -  at least one relapse (or attack) in the 12 months preceding randomization or

               -  at least two relapses (or attack) in the 24 months preceding randomization.

          -  =17 years of age and =10 years of age at randomization.

          -  Signed informed consent/assent obtained from patient and patient's legal
             representative (parents or guardians) according to local regulations.</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  EDSS score &gt; 5.5 at screening or randomization visits.

          -  Relapse within 30 days prior to randomization.

          -  Treated with:

               -  glatiramer acetate, interferons, or dimethyl fumarate within 1 month prior to
                  randomization

               -  fingolimod, or intravenous immunoglobulins within 3 months prior to randomization

               -  natalizumab, other immunosuppressant or immunomodulatory agents such as
                  cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, within
                  6 months prior to randomization,

               -  cladribine or mitoxantrone within 2 years prior to randomization.

          -  Treated with alemtuzumab at any time.

          -  History of HIV infection.

          -  Contraindication for MRI.

          -  Pregnant or breast-feeding females or those who plan to become pregnant during the
             study.

          -  Female patients of child-bearing potential not using highly effective contraceptive
             method (contraception in both female and male is required).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>16/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>165</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>22/10/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036001 - Parkville/Melbourne</hospital>
    <postcode>3052 - Parkville/Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changchun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changsha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chengdu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chongqing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shijiazhuang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Taiyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin Bicetre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Morocco</country>
      <state>Fes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Morocco</country>
      <state>Marrakech</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Murcia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Manouba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Sfax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Trabzon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genzyme, a Sanofi Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

      To assess the effect of teriflunomide in comparison to placebo on disease activity measured
      by time to first clinical relapse after randomization in children and adolescents 10 to 17
      years of age with relapsing forms of multiple sclerosis.

      Secondary Objectives:

        -  To assess the effect of teriflunomide in comparison to placebo on disease
           activity/progression measured by brain MRI and on cognitive function.

        -  To evaluate the safety and tolerability of teriflunomide in comparison to placebo.

        -  To evaluate the pharmacokinetics (PK) of teriflunomide.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02201108</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>For site information, send an email with site number to</name>
      <address />
      <phone />
      <fax />
      <email>Contact-Us@sanofi.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>